Skip to main content
Clinical Trials/JPRN-UMIN000026426
JPRN-UMIN000026426
Completed
未知

A Study on predictors of treatment response concerning of the efficacy of tolvaptan on refractory ascites. - Effect of tolvaptan on refractory ascites.

The third department of internal medicine, Nara Medical University0 sites30 target enrollmentMarch 7, 2017

Overview

Phase
未知
Intervention
Not specified
Conditions
iver cirrhosis with refractory ascites.
Sponsor
The third department of internal medicine, Nara Medical University
Enrollment
30
Status
Completed
Last Updated
2 years ago

Overview

Brief Summary

ot available

Registry
who.int
Start Date
March 7, 2017
End Date
March 31, 2023
Last Updated
2 years ago
Study Type
Interventional
Sex
All

Investigators

Sponsor
The third department of internal medicine, Nara Medical University

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • 1\) Adequate cardiac organ function a) Patients with conjestive heart failure above NYHA class3 b) Patients with severe hypertension 2\) Patients with severe and active infectious disease (exclude HBV,HCV hepatitis) 3\) Patients with HIV 4\) Patients taking dialysis 5\) Patients with portal tumor thrombosis (Vp3 or Vp4\) 6\) Patients with hepatic encephalopathy 7\) Patients with crutial digestive bleedings within 4 weeks 8\) Patients with the following treatment a) Systemic chemotherapy b) Being treated with invasive surgical therapy within 4 weeks 9\) Patients with oral intake difficulty 10\)Patients with severe digestive diseases 11\)Patients taking a tablet which would affect this clinical study 12\)Pregnant woman, lactating woman, or a woman suspected of pregnancy 13\)Patients with severe allergic reaction to Tolvaptan 14\)Patients with drug abuse or psychological disorders 15\) Patients concluded to be inappropriate to participate in this study by their physicians

Outcomes

Primary Outcomes

Not specified

Similar Trials